In this Thursday, July 12, 2012, file photo, Centrum multivitamins are shown on the packaging line at the Pfizer plant in Montreal. Pfizer Inc.'s second-quarter net income jumped 25 percent as sharply lower costs for production, marketing and restructuring more than offset a plunge in revenue from cholesterol fighter Lipitor caused by generic competition. The Viagra maker said Tuesday, July 31, 2012, that net income was $3.25 billion, or 43 cents per share, up from $2.61 billion, or 33 cents per share, a year earlier. (AP Photo/The Canadian Press, Graham Hughes, File)
Big Pharma

Why Is UCLA Doing Pfizer’s Dirty Work in India?

A university develops a breakthrough prostate cancer drug—and then fights to keep it priced beyond reach.